Month: January 2024

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin’s appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Lead, RSV at GSK. In this capacity, he was responsible for the successful commercial launch of GSK’s RSV product AREXVY. Prior to that Mr. McLoughlin...

Press ReleaseNokia and Zayo achieve new North American distance record for 800Gb/s transmission on live networkNorth American transmission record of 800Gb/s over 1866km using a single wavelength over 23 spans over a C+L WDM line system Companies also achieved single wavelength one Terabit per second (1 Tb/s) transmission over 1004kms using 150GHz channels showing ability to reach even higher capacity on high traffic routes Challenging distance records addresses soaring traffic demand resulting from an increasingly digitized world18 Jan 2023Espoo, Finland – Nokia and Zayo have announced the successful completion of a live field trial of Nokia’s sixth-generation Photonic Service Engine super-coherent optics (PSE-6s), demonstrating a North American transmission record of 800Gb/s over a single wavelength from LA to El Paso on a...

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online. The presentation will highlight initial...

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2024 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX Best Market, based on an equal weighting of one-year total return and average daily dollar volume growth. Companies in the 2024 OTCQX Best 50 were ranked based on their performance during the 2023 calendar year. “We congratulate this year’s OTCQX Best 50 companies on their ability to achieve a high level of performance during another challenging year for market conditions,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “This year’s roster represents a diverse set of industries and geographies...

– The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis – The raise also includes a $450 million credit facility from Blue Owl that refinances existing senior secured credit, extending maturity from 2026 to 2029 subject to certain conditions – Additionally, the agreement with Blue Owl provides for the possibility of additional incremental facilities of up to $300 million of credit to support strategic pipeline expansion and acceleration – With this financing BridgeBio enters 2024 well capitalized to launch acoramidis and continue to accelerate its industry-leading genetic medicine R&D engine PALO ALTO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage...

BUFORD, Ga., Jan. 18, 2024 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (the “Company” or “OneWater”) announced today that it will release its first quarter 2024 financial results on Thursday, February 1st, 2024, before the market opens. Following the release, the Company’s management team will host a conference call to discuss the results at 8:30 a.m. Eastern Time that day. To access via phone, participants can use the dial in below: Event: OneWater Marine Inc. Fiscal First Quarter 2024 Conference Call Date: Thursday, February 1, 2024 Time: 8:30 a.m. Eastern Time Live Call: 1-833-630-0581 or 1-412-317-1814 (International) OneWater Marine will offer a live and archived webcast of the conference call, accessible from the Investor Relations section of the company’s website, at https://investor.onewatermarine.com/...

Amendment to Purchase Agreement Executed Including Shares for Debt CALGARY, Alberta, Jan. 18, 2024 (GLOBE NEWSWIRE) — Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a waste-to-fuel environmental technology company, announces today that it has executed an amendment (the “Amendment”) to the agreement of purchase and sale (the “PSA”) with Renewable U Energy Inc. (“Renewable U”) regarding the purchase by Cielo of land in Dunmore, Alberta (the “Dunmore Land”) for the purposes of building a full-scale, waste-to-fuel facility (the “Dunmore Facility”).   On May 1st, 2023, Cielo announced its agreement with Renewable U to acquire the Dunmore Land, which provided for a condition deadline as well as a tentative closing date, both of which have been amended since the date of the initial agreement, as previously...

VANCOUVER, British Columbia, Jan. 18, 2024 (GLOBE NEWSWIRE) — Anfield Energy, Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to provide a corporate review of 2023 and discuss its 2024 plans. Anfield continues its advance towards U.S.-based uranium and vanadium production and is poised to benefit from the escalating world-wide demand for uranium. Corey Dias, Anfield CEO states, “We at Anfield are very proud of our transformational 2023 accomplishments to meet our production goals. Given our 2023 accomplishments and continued furtherance of our two-fold production strategy – underpinned by the licensed, permitted and constructed Shootaring Canyon mill – we expect to see the valuation gap between Anfield and other producing and near-producing peers narrow significantly in 2024. Significant...

Figure 1Surface Map of the Mirage Project and Drill Holes Completed to DateFigure 2Cross Sections A to A’ Along Dyke MR-6MONTREAL, Jan. 18, 2024 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to report final drill results from the Fall 2023 program at the Mirage Project, located in the Eeyou Istchee-James Bay region of Quebec. Drilling has outlined two new spodumene mineralized dykes (MR-5 and MR-6) with significant thickness and grade, all within the Central Zone. Highlights includeMR-23-28 intersected high-grade mineralization of 1.80% Li2O over 37.2 meters starting from surface in newly discovered dyke MR-6 located 500 metres northeast of MR-3. Evidence of potential stacking of dykes in Central Zone where MR-23-35 intercepted 11.5 meters grading...

VANCOUVER, British Columbia, Jan. 18, 2024 (GLOBE NEWSWIRE) — MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) has announced today that it has achieved its near term goal of total clinic revenue under management with MedMatrix, the AI-powered data analytics platform. 14 clinics in total across the US and Canada, representing an estimated US$100M in total clinic revenue1, are now using MedMatrix. “The adoption of MedMatrix has been extraordinary, with multiple clinic groups signing on in just two short months,” said Dr. Jaime Gerber, Chairman of MedBright AI. “We look forward to continued expansion to many more clinic groups and continuing our rapid growth trajectory.” MedBright AI is the primary shareholder in MedMatrix, an AI-powered data analytics platform. MedMatrix harnesses the...